Minimal Toxicity and Mortality in High-Risk Breast Cancer Patients Receiving High-Dose Cyclophosphamide, Thiotepa, and Carboplatin Plus Autologous Marrow/Stem-Cell Transplantation and Comprehensive Supportive Care

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1156-1164

  Holland, H Kent ^a,b   Dix, Suzanne P ^a   Geller, Robert B ^a   Devine, Steve M ^a   Heffner, Leonard T ^a   Connaghan, D Gerard ^a   Hillyer, Christopher D ^a   Hughes, Lori L ^a   Miller, Robin L ^a   Moore, Melvin R ^a   Winton, Elliott F ^a   Wingard, John R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUCONAZOLE; NORFLOXACIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; ALGORITHMS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0029966674     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1156     Document Type: Article

References (39)

1. Vincent MD, Powles TJ, Coombes RC, et al: Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 21:255-260, 1988
2. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
3. Kaminer LS, Williams SF, Beschorner J, et al: High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast cancer. Bone Marrow Transplant 4:359-362, 1989
4. Williams SF, Mick R, Desser R, et al: High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7:1824-1830, 1989
5. Williams SF, Gilewski T, Mick R, et al: High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10:1743-1747, 1992
6. Pittman KB, To LB, Bayly JL, et al: Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transplant 10:535-540, 1992
7. Klumpp TR, Mangan KF, Glenn LD, et al: Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 11:337-339, 1993
8. Mulder NH, Mulder POM, Sleijfer DT, et al: Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer 29A:668-671, 1993
9. Fields KK, Elfenbein GJ, Perkins JB, et al: Two novel high-dose treatment regimens for metastatic breast cancer - Ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: Outcomes and toxicities. Semin Oncol 20:59-66, 1993
10. de Graaf H, Willemse PHB, de Vries EGE, et al: Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 30 A:150-153, 1993
11. Myers SE, Mick R, Williams SF: High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplant. Bone Marrow Transplant 13:449-454, 1994
12. North American Autologous Bone Marrow Transplantation Registry Data, Milwaukee, WI, 1994
13. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
14. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatinum with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
15. + hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy. Autologous Marrow and Blood Transplantation, Proceeding of the Seventh International Symposium, Arlington, TX, August 17-20, 1994
16. McDonald GB, Sharma P, Matthews D, et al: Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 4:116-122, 1984
17. McDonald GB, Hinds MS, Fisher LD, et al: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255-267, 1993
18. Peters WP, Fay JW, Holland HK, et al: Autologous bone marrow transplantation as adjuvant therapy in primary breast cancer: The American experience. Keystone Symposium on BMT, 1995 (in press)
19. Wingard JR: Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 6:371-383, 1990
20. Saral R, Burns WH, Laskin O, et al: Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone marrow transplant recipients. N Engl J Med 305:63-67, 1981
21. Wingard JR: Infectious and noninfectious systemic consequences. Oral complications of cancer therapies: Diagnosis, prevention, and treatment. NCI Monogr 9:21-26, 1990
22. Karp JE, Merz WG, Hendrickson C, et al: Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 106:1-7, 1987
23. Karp JE, Kick J, Angelopulos C, et al: The role of low dose vancomycin used prophylactically to prevent multi-port central venous catheter infection during deep granulocytopenia. Proceedings of the 30th Interscience Conference on Antimicrobial Agents in Chemotherapy, Atlanta. GA, October 21-24, 1990
24. Karp JE, Dick JD, Angelopulos C: Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 81:237-242, 1986
25. Steiner M: Alpha-streptococcal shock in bone marrow transplantation patients. Blood 73:409, 1988 (suppl 1, abstr)
26. Ringden O, Heimdahl A, Lonnqvist B: Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplantation recipients after the introduction of acyclovir. Lancet:744, 1984 (letter)
27. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845-851, 1992
28. Jones RJ, Lee KSK, Beschorner WE, et al: Venocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778-783, 1987
29. Ayash LJ, Hunt M, Antman K, et al: Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumor and lymphomas. J Clin Oncol 8:1699-1706, 1990
30. Frickhofen N, Wiesneth M, Jainta C, et al: Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 83:1998-2004, 1994
31. Wingard JR, Niehaus CS, Peterson DE, et al: Oral mucositis after bone marrow transplantation. Oral Surg Oral Med Oral Pathol 72:419-424, 1991
32. Bearman SI, Anderson GL, Mori M, et al: Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marow transplantation. J Clin Oncol 11:1729-1724, 1993
33. Bearman SI, Shuhart MC, Hinds MS, et al: Recombinant human tissue plasminogen activator for the treatment of established severe venoocclusive disease of the liver after bone marrow transplantation. Blood 80:2458-2562, 1992
34. Essell JH, Thompson JM, Harman GS, et al: Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplantation patients. Bone Marrow Transplant 10:367-372, 1992
35. Attal M, Huguet F, Rubie H, et al: Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 79:2834-2840, 1992
36. Devine SM, Winton EF, Holland HK, et al: Simultaneous administration of interleukin-6 (rhIL-6) and Neupogen (rhG-CSF) following autologous bone marrow transplantation (ABMT) for breast cancer (BCA). Blood 84:89a, 1994 (suppl 1, abstr 343)
37. Holland HK, Moore MR, Winton EF, et al: Hematological recovery after high-dose chemotherapy (HDC) for breast cancer (BrCa) with rhu-GF is similar between autologous bone marrow transplantation (ABMT) vs peripheral blood stem cell (PBSC) mobilization. Proc Am Soc Clin Oncol 12:37, 1993 (abstr)
38. Gilbert C, Meisengerg B, Vredenburgh J, et al: Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12:1005-1011, 1994
39. Geller RB, Gilmore CE., Dix SP, et al: A randomized, dose escalation trial of octreotide versus loperamide for chemotherapy induced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol 50:167-172, 1995